STOCK TITAN

Astrazeneca plc - AZN STOCK NEWS

Welcome to our dedicated news page for Astrazeneca plc (Ticker: AZN), a resource for investors and traders seeking the latest updates and insights on Astrazeneca plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Astrazeneca plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Astrazeneca plc's position in the market.

Rhea-AI Summary
Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) is entitled to receive a $10 million milestone payment from AstraZeneca (LSE/STO/Nasdaq: AZN) after the first patient was dosed in AstraZeneca's ARTEMIDE-Bil01 trial with rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical-stage anti-TIGIT antibody, COM902.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.86%
Tags
clinical trial
-
Rhea-AI Summary
Turbine (AZN): Turbine, a leading biological simulation company, collaborates with AstraZeneca to identify resistance mechanisms in hematological cancers using its Simulated Cell™ platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
none
-
Rhea-AI Summary
Allorion Therapeutics (AZN) announces an exclusive option and global license agreement with AstraZeneca for a novel EGFR L858R allosteric inhibitor program, aiming to treat advanced EGFR-mutant non-small cell lung cancer. The agreement includes upfront and near-term payments of up to $40 million, additional milestone payments of over $500 million, and tiered royalties on net sales worldwide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
none
Rhea-AI Summary
AstraZeneca (NASDAQ: GRCL) to acquire Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company developing innovative cell therapies for cancer and autoimmune diseases. The acquisition will enrich AstraZeneca's pipeline with a novel, clinical-stage FasTCAR-enabled BCMA and CD19 dual-targeting autologous chimeric antigen receptor T-cell (CAR-T) therapy, GC012F, with a transaction value of approximately $1.2bn.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.32%
Tags
acquisition
-
Rhea-AI Summary
AstraZeneca (NASDAQ: GRCL) to acquire Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company developing innovative cell therapies for cancer and autoimmune diseases. The acquisition will enrich AstraZeneca's pipeline with a novel, clinical-stage FasTCAR-enabled BCMA and CD19 dual-targeting autologous chimeric antigen receptor T-cell (CAR-T) therapy, GC012F, with a transaction value of approximately $1.2bn.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
60.26%
Tags
acquisition
-
Rhea-AI Summary
AstraZeneca and Ionis' WAINUA™ (eplontersen) has been approved by the US FDA for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. The approval is based on the NEURO-TTRansform Phase III trial, showing consistent and sustained benefit in improving neuropathy impairment and quality of life. WAINUA is the only approved medicine for ATTRv-PN that can be self-administered via an auto-injector.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.02%
Tags
none
Rhea-AI Summary
Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) to receive $10 million milestone payment from AstraZeneca for dosing the first patient in Phase 3 trial of rilvegostomig, a PD-1/TIGIT bispecific antibody
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.08%
Tags
clinical trial
-
Rhea-AI Summary
Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) to receive $10 million milestone payment from AstraZeneca for dosing the first patient in Phase 3 trial of rilvegostomig, a PD-1/TIGIT bispecific antibody
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
173.97%
Tags
clinical trial
-
Rhea-AI Summary
Daiichi Sankyo (4568) and AstraZeneca (AZN) initiate two global, randomized phase 3 trials for neoadjuvant and advanced triple negative breast cancer treatments with datopotamab deruxtecan and durvalumab.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.77%
Tags
clinical trial
Rhea-AI Summary
AstraZeneca (NASDAQ: ICVX) has entered into a definitive agreement to acquire Icosavax, Inc., a US-based clinical-stage biopharmaceutical company focused on developing differentiated, high-potential vaccines using an innovative, protein virus-like particle (VLP) platform. The proposed acquisition will strengthen AstraZeneca’s Vaccines & Immune Therapies late-stage pipeline with Icosavax’s lead investigational vaccine candidate, IVX-A12, targeting both RSV and hMPV, two leading causes of severe respiratory infection and hospitalization in adults 60 years of age and older and those with chronic conditions. The upfront cash portion of the consideration represents a transaction value of approximately $0.8bn, a 43% premium to Icosavax’s closing market price on 11th December 2023. Combined, the upfront and maximum potential contingent value payments represent, if achieved, a transaction value of approximately $1.1bn, a 91% premium to Icosavax’s closing market price on 11th December 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
acquisition clinical trial
Astrazeneca plc

Nasdaq:AZN

AZN Rankings

AZN Stock Data

211.63B
1.54B
0.01%
16.79%
0.3%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United Kingdom
Cambridge

About AZN

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.